2. Search Result
Search Result
Results for "

NK-cell

" in MedChemExpress (MCE) Product Catalog:

104

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

13

Peptides

42

Inhibitory Antibodies

12

Natural
Products

38

Recombinant Proteins

2

Isotope-Labeled Compounds

6

Antibodies

6

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12005
    Fingolimod hydrochloride
    Maximum Cited Publications
    76 Publications Verification

    FTY720

    		 LPL Receptor PAK Inflammation/Immunology Cancer
    Fingolimod (FTY720) hydrochloride is a sphingosine 1-phosphate (S1P) antagonist with IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride is also a pak1 activator and immunosuppressant .
    Fingolimod hydrochloride
  • HY-116282
    Dextran sulfate sodium salt (MW 5000)
    5 Publications Verification

    DSS (MW 5000); DXS (MW 5000)

    		 HIV Complement System Apoptosis Infection Inflammation/Immunology
    Dextran sulfate sodium salt (DSS) (MW 5000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt (DSS) with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 5000) is an inhibitor of complement and coagulation pathways, and belongs to the glycosaminoglycans (GAG) family. Dextran sulfate sodium salt (MW 5000) acts as an anticoagulant, antiviral, and anti-lipemic agent. Dextran sulfate sodium salt (DSS) stops HIV-1 virus adsorption to host cells. Dextran sulfate sodium salt (MW 5000) prevents NK cell-mediated cytotoxicity. Dextran sulfate sodium salt (MW 5000) inhibits instant blood-mediated inflammatory reaction (IBMIR) .
    Dextran sulfate sodium salt (MW 5000)
  • HY-11063
    Fingolimod
    Maximum Cited Publications
    76 Publications Verification

    FTY720 free base

    		 LPL Receptor PAK Infection Neurological Disease Inflammation/Immunology Cancer
    Fingolimod (FTY720 free base) is a brain-penetrant sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant .
    Fingolimod
  • HY-P10587
    Icotrokinra

    JNJ-77242113; JNJ-2113; PN-235

    		 Interleukin Related STAT IFNAR Inflammation/Immunology
    Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
    Icotrokinra
  • HY-N7075
    Inulin
    4 Publications Verification

    		 Endogenous Metabolite Infection Neurological Disease Metabolic Disease Cancer
    Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; Enhancing the intestinal barrier function and reducing endotoxin translocation; Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].
    Inulin
  • HY-116282A
    Dextran sulfate sodium salt (MW 4500-5500)

    DSS (MW 4500-5500); DXS (MW 4500-5500)

    		 HIV Apoptosis Complement System Infection Inflammation/Immunology
    Dextran sulfate sodium salt (DSS) (MW 4500-5500) is a polymer of dehydrated glucose with a molecular weight of approximately 4500-5500. Dextran sulfate sodium salt with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 4500-5500) is an inhibitor of complement and coagulation pathways, and belongs to the glycosaminoglycans (GAG) family. Dextran sulfate sodium salt (MW 4500-5500) acts as an anticoagulant, antiviral, and anti-lipemic agent. Dextran sulfate sodium salt (MW 4500-5500) stops HIV-1 virus adsorption to host cells. Dextran sulfate sodium salt (MW 4500-5500) prevents NK cell-mediated cytotoxicity. Dextran sulfate sodium salt (MW 4500-5500) inhibits instant blood-mediated inflammatory reaction (IBMIR) .
    Dextran sulfate sodium salt (MW 4500-5500)
  • HY-N0637
    Eriodictyol
    Maximum Cited Publications
    13 Publications Verification

    Huazhongilexone

    		 Melanocortin Receptor TRP Channel Infection Inflammation/Immunology
    Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC50=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases .
    Eriodictyol
  • HY-163028
    ML-T7

    		Tim3 Cancer
    ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
    ML-T7
  • HY-N0594
    Deacetylasperulosidic Acid

    		SOD Interleukin Related TNF Receptor Inflammation/Immunology
    Deacetylasperulosidic Acid is an orally active antioxidant. Deacetylasperulosidic Acid exerts a definite in vivo antioxidant effect and alleviates oxidative stress injury by enhancing SOD activity. In atopic dermatitis models, Deacetylasperulosidic Acid corrects Th2-skewed immune imbalance and reduces allergy-related factors; in immunosuppression models, it activates cellular immunity, enhances NK cell activity and IL-2 production. Deacetylasperulosidic Acid can be used in the research of atopic dermatitis .
    Deacetylasperulosidic Acid
  • HY-P99419
    Acasunlimab

    GEN1046

    		 PD-1/PD-L1 Cancer
    Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .
    Acasunlimab
  • HY-P5307
    Peptide A5K

    INF7-A5K-TAT

    		 Biochemical Assay Reagents Others
    Peptide A5K (INF7-A5K-TAT) is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .
    Peptide A5K
  • HY-175751
    LRK-4189

    		mTOR Cancer
    LRK-4189 is an orally active PIP4K2C (a regulator of mTOR complex) degrader and type 1 immune activator. LRK-4189 induces the degradation of the lipid kinase PIP4K2C. LRK-4189 triggers the interferon signaling pathway in microsatellite-stable (MSS) colorectal cancer cells, activates immunogenic tumor killing, and induces endogenous cell death. LRK-4189 sensitizes microsatellite-stable colorectal cancer tumors to NK cell killing and dendritic cell phagocytosis. LRK-4189 can be used for the research of microsatellite-stable colorectal cancer .
    LRK-4189
  • HY-N2424
    Flavone

    2-Phenyl-4-chromone

    		 CDK Apoptosis Caspase Cancer
    Flavone is an anti-tumor compound that targets cell cycle regulatory proteins (such as cyclin B1) and apoptosis-related factors (such as p21waf1, PIG3). Flavone selectively induces mitochondrial-mediated apoptosis pathways in tumor cells, inhibits cyclin B1 protein expression, upregulates p21waf1, and activates p63/p73 proteins. Flavone has immunomodulatory functions that enhance natural killer cell (NK cell) activity and lymphocyte proliferation. Flavone is used in cancer research, especially for its inhibitory potential in solid tumor models such as esophageal cancer and liver cancer .
    Flavone
  • HY-N0637A
    (±)-Eriodictyol

    (±)-Huazhongilexone; Dihydroluteolin

    		 Melanocortin Receptor TRP Channel Metabolic Disease
    (±)-Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC50=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. (±)-Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. (±)-Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. (±)-Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. (±)-Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases .
    (±)-Eriodictyol
  • HY-Y0493
    HODHBt

    HOOBt

    		 STAT HIV Infection Cancer
    HODHBt (HOOBt) inhibits STAT5-SUMO interaction by blocking SUMOylation of phosphorylated STAT5. HODHBt enhances the magnitude of IL-15 signaling and significantly increases the natural killer (NK) cell cytotoxicity phenotype and function and the generation of cytokine-induced memory-like (CIML) natural killer (NK) cells. HODHBt can be used for research of HIV-infection and cancer .
    HODHBt
  • HY-P99032
    Monalizumab
    5 Publications Verification

    IPH2201

    		 Checkpoint Kinase (Chk) IFNAR Inflammation/Immunology Cancer
    Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
    Monalizumab
  • HY-160041A
    Olaptesed pegol sodium

    NOX-A12 sodium

    		 CXCR Cancer
    Olaptesed pegol (NOX-A12) sodium is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol sodium can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol sodium can be used for researches of colon cancer and lymphocytic leukemia .
    Olaptesed pegol sodium
  • HY-160041
    Olaptesed pegol

    NOX-A12

    		 CXCR Cancer
    Olaptesed pegol (NOX-A12) is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol can be used for researches of colon cancer and lymphocytic leukemia .
    Olaptesed pegol
  • HY-P99143
    Anti-Mouse NK1.1 Antibody (PK136)

    		Neurokinin Receptor NF-κB STAT Inflammation/Immunology
    Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .
    Anti-Mouse NK1.1 Antibody (PK136)
  • HY-108738
    Daclizumab

    Ro 24-7375

    		 Interleukin Related Apoptosis Inflammation/Immunology Cancer
    Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research .
    Daclizumab
  • HY-P99157
    Omburtamab

    		CD276/B7-H3 Cancer
    Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
    Omburtamab
  • HY-P99661
    Inbakicept
    2 Publications Verification

    		 Interleukin Related Cancer
    Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
    Inbakicept
  • HY-P990680
    Anti-Mouse CD40 Antibody (FGK4.5/FGK45)

    		Transmembrane Glycoprotein TNF Receptor Infection Inflammation/Immunology Cancer
    Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonal antibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation .
    Anti-Mouse CD40 Antibody (FGK4.5/FGK45)
  • HY-P99291
    Etaracizumab

    LM609; MEDI-522

    		 Integrin Apoptosis Akt Cancer
    Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Etaracizumab
  • HY-P990710
    Acimtamig

    AFM13

    		 TNF Receptor Cancer
    Acimtamig (AFM13) is a CD30/CD16A bispecific innate cell engager. Acimtamig binds to the CD16A expressed on natural killer (NK) cells and binds to CD30 on CD30-expressing tumor cells, thereby selectively cross-linking tumor and NK cells. Acimtamig can be used for the study of eripheral T-cell lymphoma (PTCL) .
    Acimtamig
  • HY-P990017
    Englumafusp alfa

    CD19-4-1BBL; RO7227166; RG6076

    		 CD19 Cancer
    Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .
    Englumafusp alfa
  • HY-153793
    Alcudacigib

    DGKζ-IN-1

    		 DGK IFNAR Interleukin Related ERK Cancer
    Alcudacigib (ASP1570; DGKζ-IN-1) is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC50 of 4.7 nM against human DGKζ and an IC50 of 3.0 nM against mouse DGKζ. Alcudacigib selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib enhances the anti-tumor functions of T cells and NK cells. Alcudacigib can be used for the research of advanced/metastatic solid tumors .
    Alcudacigib
  • HY-160696
    ORIC-533

    		CD73 Cancer
    ORIC-533 is an orally active, highly selective, AMP-competitive CD73 inhibitor that potently blocks adenosine production with sub-nanomolar affinity (Ka=0.03 nM). In multiple myeloma, ORIC-533 restores and enhances the cytotoxicity of the immune system against tumor cells through multiple immunological mechanisms, including reversing the immunosuppressive microenvironment, inducing immunogenic cell death, and activating dendritic cells, T cells and NK cells, with no direct toxicity to normal cells. The combination of ORIC-533 with Daratumumab (HY-P9915) synergistically enhances anti-tumor efficacy, significantly increases intratumoral CD8 + T cell infiltration and inhibits tumor growth in vivo .
    ORIC-533
  • HY-137295
    Ingenol 3,20-dibenzoate

    		PKC Apoptosis Inflammation/Immunology
    Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells .
    Ingenol 3,20-dibenzoate
  • HY-125938
    Cycloartenyl ferulate
    1 Publications Verification

    Cycloartenol ferulate; Cycloartenol ferulic acid ester

    		 Drug Derivative Apoptosis Reactive Oxygen Species (ROS) JAK STAT Inflammation/Immunology Cancer
    Cycloartenyl ferulate (Cycloartenol ferulate; Cycloartenol ferulic acid ester) is a derivative of γ-oryzanol (HY-B2194) with multiple biological activities including antioxidant, anti-inflammatory, and anti-tumor properties. Cycloartenyl ferulate selectively binds to IFNγR1 (binding affinity Kd = 0.5 μM) to activate the canonical JAK1/2-STAT1 signaling pathway. Cycloartenyl ferulate inhibits paraquat (PQ)-triggered apoptosis and ROS in HK2 cells. Cycloartenyl ferulate enhances the activation and cytolytic activity of natural killer (NK) cells by upregulating the expression of NK cell activation receptors (NKG2D, NKp30, NKp44) and the release of cytotoxic molecules and cytokine IFNγ. Cycloartenyl ferulate exerts anti-cancer effects in tumor mice models. Cycloartenyl ferulate can be used for the study of cancer and allergic inflammation intervention .
    Cycloartenyl ferulate
  • HY-144088
    ZYF0033
    2 Publications Verification

    HPK1-IN-22

    		 MAP4K Inflammation/Immunology Cancer
    ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a +CD8 + T cells, but not T cells, PD-1 +CD8 + T cells, TIM-3 +CD8 + Infiltration of T cells and LAG3 +CD8 + T cells was reduced .
    ZYF0033
  • HY-P990742
    Givastomig

    TJ-CD4B; ABL111; TJ033721

    		 TNF Receptor Claudin Inflammation/Immunology Cancer
    Givastomig (ABL111, TJ033721) is a bispecific antibody (BsAb) inhibitor. Givastomig can specifically binds to Claudin18.2 (CLDN 18.2) on the surface of cancer cells and 4-1BB (CD137, TNFRSF9) on the surface of activated T cells and natural killer (NK) cells. Givastomig is engineered to contain a single Fc-domain mutation (asparagine to alanine) to eliminate Fc-effector function. Givastomig-bound cell lines expressing a range of CLDN18.2 levels with high affinity and induced 4-1BB activation only in the context of CLDN18.2 binding. Givastomig can be used for the study of colon carcinoma .
    Givastomig
  • HY-11063R
    Fingolimod (Standard)

    FTY720 free base (Standard)

    		 Reference Standards LPL Receptor PAK Inflammation/Immunology Cancer
    Fingolimod (Standard) is the analytical standard of Fingolimod. This product is intended for research and analytical applications. Fingolimod (FTY720 free base) is a brain-penetrant sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant .
    Fingolimod (Standard)
  • HY-159886
    MG-C-30

    		TNF Receptor Inflammation/Immunology
    MG-C-30 is an orally active agonist for CD27 with an EC50 of 0.84 μM. MG-C-30 activates NK cells and T cell co-stimulatory signals, and enhances immune response. MG-C-30 exhibits antitumor efficacy in mouse EG7-OVA model .
    MG-C-30
  • HY-P99759
    Nogapendekin alfa (his tag)

    IL-15N72D

    		 Interleukin Related Inflammation/Immunology Cancer
    Nogapendekin alfa (his tag), a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa (his tag) promotes the proliferation and viability of immune cells. Nogapendekin alfa (his tag) combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8 + T cells .
    Nogapendekin alfa (his tag)
  • HY-153793A
    Alcudacigib TFA

    DGKζ-IN-1 TFA

    		 DGK IFNAR Interleukin Related ERK Cancer
    Alcudacigib (ASP1570; DGKζ-IN-1) TFA is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC50 of 4.7 nM against human DGKζ and an IC50 of 3.0 nM against mouse DGKζ. Alcudacigib TFA selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib TFA enhances the anti-tumor functions of T cells and NK cells. Alcudacigib TFA can be used for the research of advanced/metastatic solid tumors .
    Alcudacigib TFA
  • HY-13743
    Roquinimex

    Linomide; FCF89; ABR212616

    		 TNF Receptor Interleukin Related IFNAR Neurological Disease Inflammation/Immunology Cancer
    Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis .
    Roquinimex
  • HY-P10563
    Noraramtide

    BHV-1100

    		 CD38 Cancer
    Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
    Noraramtide
  • HY-P991309
    ZM-008

    		C-type Lectin-like Receptors (CTLRs) Cancer
    ZM-008 is an anti-LLT1 monoclonal antibody. ZM-008 blocks the interaction between LLT1 and CD161 on the surface of NK cells and T cells. ZM-008 restores anti-tumor immune activity, shifts the tumor microenvironment to an immune-responsive state, and recovers NK cell-mediated cytotoxicity against tumor cells, thereby reversing immunosuppression in immune-resistant "cold" tumors. ZM-008 is applicable to the research of immune-resistant solid tumors .
    ZM-008
  • HY-135525
    Agroclavine

    		Dopamine Receptor Adrenergic Receptor Neurological Disease Inflammation/Immunology
    Agroclavine acts as an agonist of the D1-dopamine receptor and α1-adrenergic receptor. Agroclavine enhances the sensitivity of the brain to magnetic fields; it impairs spatial memory without affecting hippocampal long-term potentiation (LTP). Agroclavine exerts bidirectional regulatory effects on immune activity: it enhances NK cell activity with low toxicity under normal conditions, while it inhibits NK cell activity and exhibits significant cardiac and hepatic toxicity under stress conditions. Agroclavine can be used for research on neuroelectrophysiology, learning and memory, and immunoregulation .
    Agroclavine
  • HY-155477
    Cbl-b-IN-15

    		E1/E2/E3 Enzyme Cancer
    Cbl-b-IN-15 (compound 25) is an inhibitor of the RING finger E3 ligase Cbl (IC50: 15 nM). Cbl-b refers to Casitas B-lineage lymphoma proto-oncogene-b, which inhibits T-cell, natural killer (NK) cell, and B-cell activation. Cbl-b-IN-15 activates T cell function with EC50=0.41 μM .
    Cbl-b-IN-15
  • HY-150749A
    ODN D-SL03 sodium

    		IFNAR Cancer
    ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
    ODN D-SL03 sodium
  • HY-P99027
    Ieramilimab

    LAG525; IMP701; Hu5A8

    		 LAG-3 Cancer
    Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
    Ieramilimab
  • HY-P990808
    Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1)

    		Interleukin Related Infection Metabolic Disease Inflammation/Immunology Cancer
    Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) is a rat-derived IgG2b κ type antibody inhibito, targeting to mouse CD122/IL-2Rβ. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can block IL-2 and IL-15. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can deplete natural killer (NK) cells and NKT cells. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can be used for the researches of cancer, infection, inflammation, immunology and metabolic disease, such as melanoma, experimental autoimmune encephalomyelitis (EAE) and diabetes .
    Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1)
  • HY-11063S
    Fingolimod-d4

    FTY720 free based-d4

    		 LPL Receptor PAK Inflammation/Immunology Cancer
    Fingolimod-d4 is the deuterium labeled Fingolimod. Fingolimod (FTY720 free base) is a brain-penetrant sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant .
    Fingolimod-d4
  • HY-P991382
    SAR-439459

    		TGF-β Receptor Cancer
    SAR-439459 is a human monoclonal antibody (mAb) targeting TGFB1/TGFβ-1. SAR-439459 blocks TGFβ-mediated pSMAD signaling, and suppression of T cells and NK cells. SAR-439459 has anti-tumor activity .
    SAR-439459
  • HY-N13614
    Centaurein

    		Bacterial IFNAR Nuclear Factor of activated T Cells (NFAT) NF-κB Infection Inflammation/Immunology
    Centaurein, a flavonoid, is an IFN-γ promoter enhancer. Centaurein up-regulates the activity of NFAT and NF-κB enhancers. Centaurein increases the IFN-γ expression in T and NK cells and the serum IFN-γ level in mice. Centaureidin completely relaxes the contractions in intact rat aortic rings. Centaurein effectively protects mice against Listeria infection [1][2][3][4].
    Centaurein
  • HY-P9994
    Pertuzumab zuvotolimod

    SBT6050

    		 Antibody-Drug Conjugates (ADCs) EGFR Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .
    Pertuzumab zuvotolimod
  • HY-P991543
    BTI-322

    		CD2 Inflammation/Immunology Cancer
    BTI-322 is a human IgG1κ antibody directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease .
    BTI-322
  • HY-P991000
    Imneskibart

    AU-007; BD-8; BDG8

    		 Interleukin Related Cardiovascular Disease Inflammation/Immunology Cancer
    Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Imneskibart

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: